Ohio Hemp THC Ban: Legal Challenges, Industry Impact & Current Status

Executive Summary

A federal judge has blocked enforcement of Ohio's hemp-derived THC product ban against multiple companies, delivering a significant legal setback to state regulators attempting to eliminate intoxicating cannabinoid products from the unregulated market. The preliminary injunction, issued in July 2026, prevents the Ohio Department of Commerce and Department of Agriculture from enforcing provisions of House Bill 524 that would have effectively banned products containing delta-8 THC, delta-10 THC, THC-O, and other hemp-derived intoxicating cannabinoids. The ruling affects dozens of Ohio hemp businesses that challenged the ban as unconstitutional and contrary to federal law, arguing the state exceeded its authority under the 2018 Farm Bill. This decision arrives as Ohio simultaneously implements its adult-use cannabis program approved by voters in November 2023, creating a complex regulatory landscape where licensed dispensaries sell regulated THC products while hemp retailers fight to preserve their market position. The case represents one of the most significant legal challenges to state-level hemp THC restrictions nationwide and could influence similar regulatory battles in other states.

Why This Matters

The Ohio hemp THC ban affects hundreds of businesses, thousands of jobs, and millions of dollars in economic activity while raising fundamental questions about state versus federal cannabis authority. Ohio's hemp industry grew rapidly following the 2018 Farm Bill, with retailers, manufacturers, and distributors building businesses around products containing hemp-derived cannabinoids. Industry estimates suggest the Ohio hemp market generates over $150 million annually, supporting approximately 2,000 jobs across cultivation, processing, retail, and distribution.

For consumers, the ban would eliminate access to products many use for wellness purposes without a medical marijuana card. Hemp-derived delta-8 THC products became popular alternatives for Ohioans seeking cannabinoid effects without entering the state's medical marijuana program, which requires physician certification and registration fees. The preliminary injunction preserves consumer access while legal proceedings continue.

The case carries implications beyond Ohio's borders. At least 15 states have enacted or proposed restrictions on intoxicating hemp-derived cannabinoids, creating a patchwork of state regulations that industry participants argue conflicts with the federal framework established by the Agriculture Improvement Act of 2018. The Ohio litigation tests whether states can effectively prohibit products that meet the federal definition of legal hemp.

For Ohio's newly licensed cannabis operators, the hemp market represents unwelcome competition. Adult-use dispensaries that invested millions in licensing, compliance, and taxation face competition from hemp retailers operating with minimal regulatory oversight and no excise taxes. This tension between regulated and unregulated markets drives much of the policy debate surrounding hemp-derived intoxicants.

Background and History

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act and legalized hemp cultivation nationwide. The statute defines hemp as cannabis containing no more than 0.3 percent delta-9 THC on a dry weight basis, distinguishing it from marijuana, which remains federally prohibited. This definition, codified at 7 U.S.C. § 1639o, created the legal foundation for the hemp industry but left ambiguity regarding hemp-derived intoxicating cannabinoids.

The Farm Bill transferred primary regulatory authority over hemp from the Drug Enforcement Administration to the United States Department of Agriculture. States received authority to develop their own hemp programs subject to USDA approval, or defer to federal regulation. Ohio established its hemp program through Senate Bill 57, effective July 30, 2019, authorizing the Ohio Department of Agriculture to license hemp cultivators and processors.

Rise of Delta-8 THC and Intoxicating Hemp Products

Following hemp legalization, manufacturers discovered methods to convert CBD into delta-8 THC, delta-10 THC, and other intoxicating cannabinoids through chemical processes. Delta-8 THC, an isomer of delta-9 THC, produces psychoactive effects while technically qualifying as a hemp derivative if the final product contains less than 0.3 percent delta-9 THC. These products appeared in Ohio retail stores, gas stations, and online marketplaces beginning in 2020, creating a largely unregulated market for intoxicating cannabinoids.

The rapid growth of hemp-derived intoxicants caught regulators unprepared. Unlike Ohio's medical marijuana program, which requires testing, labeling, and tracking through seed-to-sale systems, hemp products faced minimal oversight. Consumer safety concerns emerged regarding product potency, contamination, and access by minors. The Ohio Board of Pharmacy issued guidance in 2021 stating that delta-8 THC products violated state law, but enforcement remained limited and inconsistent.

Ohio Adult-Use Cannabis Legalization

On November 7, 2023, Ohio voters approved Issue 2, legalizing adult-use cannabis for individuals 21 and older. The initiated statute, which took effect December 7, 2023, authorized possession of up to 2.5 ounces of cannabis and home cultivation of up to six plants per individual or twelve per household. The law directed the Division of Cannabis Control within the Ohio Department of Commerce to develop regulations for commercial adult-use sales, with existing medical dispensaries receiving priority for dual licenses.

Adult-use sales commenced in Ohio on August 6, 2024, with approximately 120 dispensaries authorized to serve recreational customers. The program imposed a 10 percent excise tax on adult-use sales in addition to standard sales tax, generating significant state revenue. Licensed operators invested heavily in compliance infrastructure, security systems, and inventory tracking required under Ohio Administrative Code Chapter 3796.

House Bill 524 and the Hemp THC Ban

The Ohio General Assembly passed House Bill 524 in December 2025, establishing comprehensive restrictions on hemp-derived intoxicating cannabinoids. The legislation, which Governor Mike DeWine signed into law on December 19, 2025, prohibited the sale of products containing delta-8 THC, delta-10 THC, THC-O, HHC, and other intoxicating hemp derivatives except through licensed cannabis dispensaries. The law set an effective date of July 1, 2026, giving businesses approximately six months to comply.

House Bill 524 defined "adult use cannabis" to include any product containing total THC exceeding 0.3 percent, regardless of the source. This definition encompassed hemp-derived products that met the federal hemp definition based on delta-9 THC content alone. The statute required all intoxicating cannabinoid products to flow through Ohio's licensed cannabis supply chain, subject to testing, tracking, and taxation requirements.

Proponents argued the legislation closed a regulatory loophole allowing intoxicating products to reach consumers without safety oversight. Representative Jamie Callender, the bill's sponsor, stated the measure protected public health by ensuring product testing and age verification. The Ohio Cannabis Coalition, representing licensed operators, supported the ban as necessary to create a level playing field between regulated and unregulated markets.

Opponents characterized House Bill 524 as government overreach that would destroy legitimate businesses operating under federal law. The Ohio Hemp Association argued the state lacked authority to prohibit products meeting the federal hemp definition. Small business owners testified that compliance would require entering Ohio's limited-license cannabis market, where application costs and regulatory burdens exceeded their financial capacity.

Legal Challenge and Preliminary Injunction

On June 15, 2026, a coalition of hemp businesses filed suit in the United States District Court for the Southern District of Ohio, challenging House Bill 524 as unconstitutional and preempted by federal law. The complaint, filed in the Columbus division, named the Ohio Department of Commerce and Ohio Department of Agriculture as defendants. Plaintiffs included hemp retailers, manufacturers, and industry associations representing approximately 200 Ohio businesses.

The lawsuit advanced three primary legal theories. First, plaintiffs argued the ban violated the Commerce Clause by discriminating against interstate commerce in hemp products. Second, they claimed federal preemption under the Supremacy Clause, asserting that the 2018 Farm Bill occupied the field of hemp regulation and prohibited states from banning products meeting the federal hemp definition. Third, plaintiffs alleged the law violated due process by depriving them of property interests without adequate justification.

Plaintiffs simultaneously filed a motion for preliminary injunction seeking to block enforcement pending resolution of the case. They presented evidence of irreparable harm, including business closures, employee layoffs, and loss of customer relationships. Economic analysis submitted to the court estimated that 60 percent of Ohio hemp retailers would close within 90 days of the ban's implementation, with total economic losses exceeding $100 million.

On July 17, 2026, United States District Judge Algenon Marbley issued a preliminary injunction blocking enforcement of House Bill 524's prohibition on hemp-derived THC products. The 47-page opinion found plaintiffs demonstrated a strong likelihood of success on their preemption claim, concluding that Ohio's ban conflicted with the federal statutory scheme for hemp regulation. Judge Marbley determined that the 2018 Farm Bill's definition of hemp based solely on delta-9 THC content precluded states from prohibiting products meeting that definition, regardless of other cannabinoid content.

The court rejected Ohio's argument that the ban served legitimate public health interests, finding the state failed to demonstrate why hemp-derived intoxicants posed greater risks than alcohol or other legal substances. Judge Marbley noted that Ohio could regulate hemp products through labeling, testing, and age restrictions without imposing an outright ban. The preliminary injunction remained in effect pending trial or further court order, preserving the status quo for Ohio hemp businesses.

Key Players

Ohio Department of Commerce, Division of Cannabis Control

The Division of Cannabis Control oversees Ohio's medical and adult-use cannabis programs, including licensing, compliance, and enforcement activities. The division opposed the preliminary injunction, arguing that House Bill 524 represented a legitimate exercise of state police powers to protect public health and safety. Attorneys for the department contended that intoxicating hemp products fell outside the scope of federal hemp protections because they were manufactured through chemical conversion rather than natural extraction. The division's position aligned with licensed cannabis operators who viewed unregulated hemp products as unfair competition.

Ohio Department of Agriculture

The Ohio Department of Agriculture administers the state's hemp cultivation program under USDA oversight. The department licenses hemp growers and processors, conducts compliance testing, and enforces regulations regarding THC content in hemp crops. As a defendant in the lawsuit, the department defended House Bill 524 while acknowledging tensions between state restrictions and federal hemp policy. The agency's hemp program approved 1,847 licensed cultivators as of June 2026, representing approximately 12,000 acres of hemp cultivation statewide.

Ohio Hemp Association

The Ohio Hemp Association, a trade organization representing hemp businesses, served as a lead plaintiff in the lawsuit challenging the THC ban. The association argued that House Bill 524 would devastate an industry that operated legally under federal law and state hemp regulations. Executive Director Sarah Thompson stated the organization sought regulatory clarity rather than elimination of all oversight, proposing alternative frameworks including age restrictions, product testing, and labeling requirements. The association represented approximately 200 member businesses across cultivation, manufacturing, and retail sectors.

Ohio Cannabis Coalition

The Ohio Cannabis Coalition, representing licensed medical and adult-use cannabis operators, supported House Bill 524's restrictions on hemp-derived intoxicants. The organization argued that allowing untested, untaxed products to compete with regulated cannabis undermined the voter-approved adult-use program and created public safety risks. Coalition members invested millions in licensing fees, compliance systems, and security infrastructure required for legal cannabis operations. The group advocated for channeling all intoxicating cannabinoid products through the licensed market to ensure quality control and appropriate taxation.

Judge Algenon Marbley

United States District Judge Algenon Marbley, appointed to the Southern District of Ohio in 1997, issued the preliminary injunction blocking enforcement of the hemp THC ban. Judge Marbley's opinion emphasized the primacy of federal law in hemp regulation and questioned whether states could effectively nullify the 2018 Farm Bill through restrictive definitions of intoxicating cannabinoids. His analysis focused on statutory interpretation of the Agriculture Improvement Act and the scope of state authority under the Tenth Amendment. The ruling represented a significant judicial interpretation of the federal-state balance in cannabis policy.

Legal and Regulatory Framework

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as cannabis containing not more than 0.3 percent delta-9 THC on a dry weight basis. This definition serves as the dividing line between legal hemp and illegal marijuana under federal law. The statute removed hemp from Schedule I of the Controlled Substances Act, 21 U.S.C. § 812, eliminating federal criminal penalties for hemp cultivation, processing, and distribution.

Section 297D of the Farm Bill preserves state authority to regulate hemp production within state borders, stating that nothing in the subtitle preempts or limits state laws regulating hemp. However, the statute does not explicitly address whether states may prohibit products that meet the federal hemp definition. This ambiguity created the legal foundation for challenges to state-level hemp THC bans.

The USDA issued final regulations implementing the Farm Bill's hemp provisions on January 19, 2021, codified at 7 C.F.R. Part 990. These regulations establish requirements for hemp production plans, THC testing protocols, and disposal of non-compliant plants. The regulations focus on delta-9 THC content as the compliance metric, consistent with the statutory definition.

Ohio Revised Code and House Bill 524

House Bill 524 amended Ohio Revised Code Chapter 3796 to prohibit sale of products containing intoxicating hemp-derived cannabinoids outside the licensed cannabis market. The legislation defined "adult use cannabis" to include any product with total THC exceeding 0.3 percent, encompassing delta-8 THC, delta-10 THC, and other isomers. This definition conflicted with the federal focus on delta-9 THC alone.

Section 3796.30 of the Ohio Revised Code, as amended by House Bill 524, made it unlawful to sell intoxicating cannabinoid products without a cannabis dispensary license. Violations constituted first-degree misdemeanors, punishable by up to 180 days imprisonment and fines up to $1,000. The statute authorized the Division of Cannabis Control to issue cease-and-desist orders and seek injunctive relief against non-compliant businesses.

The legislation included limited exceptions for products containing CBD with no intoxicating cannabinoids, and for hemp biomass used in manufacturing. These carve-outs preserved some segments of Ohio's hemp industry while targeting finished products marketed for their psychoactive effects.

Supremacy Clause and Federal Preemption

The preliminary injunction rested heavily on Supremacy Clause analysis under Article VI of the United States Constitution. Judge Marbley concluded that the 2018 Farm Bill established a comprehensive federal framework for hemp regulation that preempted conflicting state laws. The court applied conflict preemption principles, finding that Ohio's ban made it impossible to comply with both federal and state law—products could simultaneously qualify as legal hemp under federal law while being prohibited under Ohio law.

The opinion distinguished between state authority to regulate hemp production (expressly preserved in the Farm Bill) and state authority to prohibit hemp products meeting the federal definition (not addressed in the statute). Judge Marbley reasoned that allowing states to ban federally legal hemp through expansive definitions of intoxicating cannabinoids would undermine Congress's intent in legalizing the hemp industry.

Commerce Clause Considerations

Plaintiffs' Commerce Clause challenge alleged that House Bill 524 discriminated against interstate commerce by favoring Ohio-licensed cannabis operators over out-of-state hemp producers. The dormant Commerce Clause prohibits states from enacting protectionist measures that burden interstate trade. While Judge Marbley's preliminary injunction focused primarily on preemption, the opinion acknowledged that the ban could impermissibly favor in-state economic interests over interstate hemp commerce.

State-by-State Breakdown of Hemp THC Regulations

Ohio

Ohio's hemp THC ban, currently blocked by preliminary injunction, would prohibit sale of delta-8 THC and similar products outside licensed dispensaries. The state's adult-use cannabis program launched in August 2024, with approximately 120 active dispensaries as of July 2026. Medical marijuana patients in Ohio can possess up to a 90-day supply as determined by physicians, while adult-use customers may purchase up to 2.5 ounces per transaction. Home cultivation is legal for adults 21 and older, with limits of six plants per individual or twelve per household. The ongoing litigation creates regulatory uncertainty for Ohio hemp businesses pending final resolution.

Colorado

Colorado has not banned hemp-derived THC products but imposed new regulations in 2023 requiring testing and labeling for products containing intoxicating cannabinoids. House Bill 23-1317 established a regulatory framework for "industrial hemp products" containing delta-8 THC and similar compounds, requiring manufacturers to register with the Colorado Department of Public Health and Environment. Products must undergo testing for potency and contaminants, display warning labels, and comply with child-resistant packaging requirements. The Colorado approach represents a middle path between outright prohibition and unregulated markets.

Oregon

Oregon banned artificially derived cannabinoids including delta-8 THC through House Bill 3000, effective July 1, 2023. The statute prohibits sale of cannabinoids created through chemical synthesis or conversion, limiting legal products to naturally occurring cannabinoids extracted from hemp. Oregon's Liquor and Cannabis Commission enforces the ban, which applies to both hemp-derived and cannabis-derived synthetic cannabinoids. The state's approach reflects concerns about manufacturing processes and product safety rather than THC content alone.

New York

New York enacted restrictions on hemp-derived cannabinoid products through emergency regulations issued by the Office of Cannabis Management in September 2023. The regulations prohibit sale of products containing more than 0.3 percent total THC, including all isomers, effectively banning delta-8 THC products. However, enforcement has been inconsistent, with many retailers continuing to sell hemp-derived intoxicants. The state's adult-use cannabis program, which began retail sales in December 2022, faces significant competition from unlicensed hemp and illicit cannabis retailers.

California

California addressed hemp-derived intoxicants through Assembly Bill 45, signed in October 2023, which brought hemp products containing THC under the state's cannabis regulatory framework. The law requires products containing any detectable amount of THC to be sold only through licensed cannabis retailers, subject to testing and taxation. Implementation has been gradual, with a compliance deadline of July 1, 2024. The California Department of Cannabis Control issued guidance clarifying that delta-8 THC and similar compounds qualify as cannabis regardless of their source, bringing them under existing regulatory authority.

Texas

Texas has not enacted a statewide ban on hemp-derived THC products, though legal ambiguity persists. The Texas Department of State Health Services issued guidance in 2021 stating that delta-8 THC is a Schedule I controlled substance, but enforcement has been limited. Some Texas cities and counties have enacted local ordinances restricting or prohibiting hemp-derived intoxicants. The state's hemp program, administered by the Texas Department of Agriculture, focuses on cultivation rather than finished products. Texas does not have a legal adult-use or medical marijuana program, making hemp-derived cannabinoids one of the few legal sources of THC in the state.

Market and Business Implications

The preliminary injunction preserves a hemp market in Ohio estimated at $150 million annually, preventing immediate business closures and job losses. Industry analysts project that a sustained ban would eliminate 60-70 percent of Ohio's hemp retail locations, primarily affecting small businesses unable to transition to the licensed cannabis market. The capital requirements for cannabis licensing—including application fees exceeding $100,000, security infrastructure, and inventory tracking systems—create barriers to entry that many hemp operators cannot overcome.

For Ohio's licensed cannabis operators, the continued availability of hemp-derived THC products represents unwelcome competition. Adult-use dispensaries pay a 10 percent excise tax on sales plus standard sales tax, while hemp retailers operate tax-free on intoxicating products. This tax differential creates price advantages for hemp products, with delta-8 THC vape cartridges typically retailing for 30-40 percent less than comparable delta-9 THC products in dispensaries. Licensed operators argue this disparity undermines the regulated market and reduces state tax revenue.

Wholesale pricing dynamics reveal market tensions. Hemp-derived delta-8 THC distillate trades at approximately $1,500-$2,000 per kilogram in bulk markets, compared to $3,000-$4,000 per kilogram for cannabis-derived delta-9 THC distillate in Ohio's licensed market. The price differential reflects lower regulatory costs, absence of seed-to-sale tracking requirements, and interstate commerce in hemp products. Manufacturers can source CBD isolate from out-of-state suppliers and convert it to delta-8 THC through chemical processes, creating supply chains unavailable to licensed cannabis operators.

Investment implications extend beyond Ohio. Multi-state operators with Ohio cannabis licenses have advocated for hemp THC restrictions to protect their market positions. Companies including Cresco Labs, Curaleaf, and Verano Holdings operate Ohio dispensaries and have supported legislative efforts to channel all intoxicating cannabinoids through licensed retailers. The preliminary injunction complicates their competitive landscape and may influence similar regulatory battles in other states where MSOs operate.

Consumer spending patterns demonstrate the hemp market's significance. Industry surveys suggest approximately 15-20 percent of Ohio adults have purchased hemp-derived THC products, with monthly spending averaging $40-$60 per consumer. This translates to a customer base of roughly 1.5 million Ohioans and annual consumer expenditures exceeding $100 million. The demographic profile skews younger and more price-sensitive than the medical marijuana patient population, with many consumers viewing hemp products as accessible alternatives to regulated cannabis.

What Experts Say

Legal scholars analyzing the Ohio decision emphasize its implications for federalism and cannabis policy. According to Professor Robert Mikos of Vanderbilt Law School, an expert on marijuana federalism, the preliminary injunction reflects judicial recognition that the 2018 Farm Bill created substantive rights for hemp businesses that states cannot eliminate through definitional expansions. Mikos noted in published analysis that the decision could influence similar cases in other jurisdictions where states have attempted to ban hemp-derived intoxicants.

Industry consultants view the ruling as a temporary reprieve rather than a permanent resolution. Cannabis attorney Garrett Graff, who represents hemp businesses in regulatory matters, stated that the preliminary injunction preserves the status quo but does not resolve fundamental questions about state authority over intoxicating hemp products. Graff emphasized that the case will likely proceed to trial, where courts will conduct fuller analysis of preemption and Commerce Clause issues.

Public health researchers have raised concerns about the safety and quality of hemp-derived THC products. According to Dr. Ryan Vandrey of Johns Hopkins University, who studies cannabinoid pharmacology, the lack of regulatory oversight for hemp products creates risks of contamination, mislabeling, and inconsistent potency. Vandrey's research has documented significant discrepancies between labeled and actual THC content in delta-8 products, with some samples containing prohibited delta-9 THC levels or harmful contaminants from chemical synthesis processes.

Economic analysts project that resolution of the Ohio litigation will influence hemp market development nationwide. According to Whitney Economics, a cannabis market research firm, the hemp-derived cannabinoid market generates approximately $2 billion in annual sales across the United States. The firm's analysis suggests that state-level bans could redirect this economic activity to licensed cannabis markets or drive it underground, depending on enforcement intensity and consumer price sensitivity.

State regulators in other jurisdictions are monitoring the Ohio case closely. According to the National Association of State Departments of Agriculture, which coordinates hemp program implementation, the preliminary injunction highlights tensions between federal hemp policy and state efforts to regulate intoxicating products. The association has called for federal clarification regarding the legal status of chemically derived cannabinoids and state authority to restrict such products.

What's Next

The preliminary injunction remains in effect pending trial or settlement, with case management deadlines extending into 2027. Judge Marbley's scheduling order sets discovery deadlines for December 2026 and a potential trial date in spring 2027. Both parties have indicated willingness to pursue the case through final judgment, suggesting resolution could take 12-18 months absent settlement.

Ohio may appeal the preliminary injunction to the United States Court of Appeals for the Sixth Circuit, though such appeals face procedural hurdles and rarely succeed in overturning preliminary injunction orders. The state could also seek to modify House Bill 524 to address the court's preemption concerns while preserving some regulatory framework for hemp-derived intoxicants. Legislative options include age restrictions, testing requirements, and labeling mandates that regulate rather than prohibit hemp THC products.

The Ohio General Assembly could revisit hemp regulation during its 2027 session. Some legislators have expressed interest in compromise approaches that preserve consumer access while addressing safety concerns. Potential legislative frameworks include registration requirements for hemp retailers, product testing standards, and potency limits for hemp-derived cannabinoids. Such measures might withstand preemption challenges while achieving public health objectives.

Federal action could resolve the underlying legal ambiguity. The Drug Enforcement Administration has authority to issue rules clarifying the status of hemp-derived cannabinoids under the Controlled Substances Act. The FDA could also exercise jurisdiction over hemp products as food additives or dietary supplements, potentially establishing national standards that preempt inconsistent state regulations. However, federal agencies have shown limited appetite for comprehensive hemp cannabinoid regulation, leaving states to navigate legal uncertainty.

The case calendar includes several key decision points. Discovery closes in December 2026, followed by summary judgment motions in January 2027. If the case proceeds to trial, a verdict could arrive by summer 2027, with appeals potentially extending into 2028. The preliminary injunction preserves the status quo throughout this timeline, allowing hemp businesses to continue operations while legal issues are resolved.

Market participants are preparing for multiple scenarios. Hemp retailers are diversifying product offerings to reduce dependence on intoxicating cannabinoids, expanding into CBD wellness products and non-intoxicating formulations. Some businesses are pursuing cannabis licenses to position themselves for potential market consolidation. Licensed cannabis operators are advocating for stricter enforcement of existing regulations while the litigation proceeds.

Further Reading

• Agriculture Improvement Act of 2018, Public Law 115-334, 7 U.S.C. § 1639o et seq. - https://www.congress.gov/bill/115th-congress/house-bill/2
• Ohio Revised Code Chapter 3796 (Cannabis Control) - https://codes.ohio.gov/ohio-revised-code/chapter-3796
• USDA Hemp Regulations, 7 C.F.R. Part 990 - https://www.federalregister.gov/documents/2021/01/19/2021-00967/establishment-of-a-domestic-hemp-production-program
• Ohio Department of Agriculture Hemp Program - https://agri.ohio.gov/divisions/plant-health/hemp
• Ohio Division of Cannabis Control - https://cannabis.ohio.gov/
• Controlled Substances Act, 21 U.S.C. § 812 (Schedule I) - https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm
• Ohio Issue 2 (2023) Adult Use Cannabis Initiated Statute - Full text and results - https://ballotpedia.org/Ohio_Issue_2
• National Association of State Departments of Agriculture Hemp Resources - https://www.nasda.org/topics/hemp